| Literature DB >> 31888194 |
Julie Gatien1, Pascal Mermillod2, Guillaume Tsikis2, Ophélie Bernardi2, Sarah Janati Idrissi1, Rustem Uzbekov3,4, Daniel Le Bourhis1, Pascal Salvetti1, Carmen Almiñana2,5, Marie Saint-Dizier2,6.
Abstract
Oviductal extracellular vesicles (oEVs) have been proposed as key modulators of gamete/embryo maternal interactions. The aim of this study was to examine the metabolite content of oEVs and its regulation across the estrous cycle in cattle. Oviductal EVs were isolated from bovine oviducts ipsilateral and contralateral to ovulation at four stages of the estrous cycle (post-ovulatory stage, early and late luteal phases, and pre-ovulatory stage). The metabolomic profiling of EVs was performed by proton nuclear magnetic resonance spectroscopy (NMR). NMR identified 22 metabolites in oEVs, among which 15 were quantified. Lactate, myoinositol, and glycine were the most abundant metabolites throughout the estrous cycle. The side relative to ovulation had no effect on the oEVs' metabolite concentrations. However, levels of glucose-1-phosphate and maltose were greatly affected by the cycle stage, showing up to 100-fold higher levels at the luteal phase than at the peri-ovulatory phases. In contrast, levels of methionine were significantly higher at peri-ovulatory phases than at the late-luteal phase. Quantitative enrichment analyses of oEV-metabolites across the cycle evidenced several significantly regulated metabolic pathways related to sucrose, glucose, and lactose metabolism. This study provides the first metabolomic characterization of oEVs, increasing our understanding of the potential role of oEVs in promoting fertilization and early embryo development.Entities:
Keywords: NMR; amino acids; energy substrates; exosomes; extracellular vesicles; fallopian tube; metabolomics; oviduct
Mesh:
Year: 2019 PMID: 31888194 PMCID: PMC6941065 DOI: 10.3390/ijms20246339
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Samples of bovine oviductal extracellular vesicles (oEVs) used for proton nuclear magnetic resonance spectroscopy (NMR) analysis.
| Stage of the Cycle | No. Animals 1 | Side Relative to Ovulation | Number of OF Pools | Volume (µL) of OF before oEV Isolation | Protein Concentration (mg mL−1) |
|---|---|---|---|---|---|
| Post-ovulatory | 54 | Ipsilateral | 4 | 320–420 | 10.4–13.6 |
| Contralateral | 4 | 288–385 | 9.7–17.4 | ||
| Mid-luteal | 40 | Ipsilateral | 3 | 355–400 | 11.4–12.6 |
| Contralateral | 3 | 305–410 | 11.1–13.5 | ||
| Late-luteal | 34 | Ipsilateral | 3 | 315–470 | 9.4–10.3 |
| Contralateral | 3 | 350–470 | 13.1–15.9 | ||
| Pre-ovulatory | 40 | Ipsilateral | 3 | 450–495 | 10.0–15.2 |
| Contralateral | 3 | 500–580 | 12.0–13.4 |
1 Number of animals used to obtain 3–4 pools of oviductal fluid (OF) per stage × side with a minimum volume of 280 µL/pool that was used for oEV isolation.
Figure 1Characterization of bovine oviductal extracellular vesicles (oEVs). Representative images of exosomes (30–100 nm) and microvesicles (>100 nm) in oEV preparations observed by transmission electron microscopy (TEM) across the estrus cycle (a) and Western blotting characterization of bovine oEVs for known exosomal protein markers (b). A pool of samples from four different stages was used, showing that oEVs were positive for CD81, HSP70, and ANXA1.
Metabolites identified in bovine oviductal extracellular vesicles across the estrous cycle, ordered by chemical classes 1.
| Metabolite | Chemical Taxonomy | Identified (I)/Quantified (Q) | Function |
|---|---|---|---|
| Valine | Amino acids, peptides, and analogues | I/Q | Involved in stress, energy and muscle metabolism |
| Threonine | Amino acids, peptides, and analogues | I | Involved in biosynthesis of proteins |
| Methionine | Amino acids, peptides, and analogues | I/Q | Required for normal growth and development |
| Leucine | Amino acids, peptides, and analogues | I | Involved in biosynthesis of proteins, stress, energy, and muscle metabolism. |
| Isoleucine | Amino acids, peptides, and analogues | I/Q | Involved in stress, energy and muscle metabolism. |
| Proline | Amino acids, peptides, and analogues | I | Involved in biosynthesis of proteins |
| Glycine | Amino acids, peptides, and analogues | I/Q | Involved in the body’s production of DNA, phospholipids, and collagen, and in release of energy. |
| Alanine | Amino acids, peptides, and analogues | I/Q | One of the most important amino acids released by muscle, functioning as a major energy source. Regulator of glucose metabolism, lymphocyte reproduction and immunity. |
| Glutamate | Amino acids, peptides, and analogues | I | Involved in biosynthesis of proteins |
| Creatine | Amino acids, peptides, and analogues | I/Q | Role in energy metabolism. Responsible for the production of ATP in skeletal muscle through the process of oxidative phosphorylation inside the mitochondria. |
| Ethanolamine | Amines | I | Widely distributed in biological tissue and is a component of lecithin. |
| Carnitine | Quaternary ammonium salts | I/Q | Important in providing energy to muscles |
| Choline | Quaternary ammonium salts | I/Q | Considered an essential vitamin. |
| Lactate | Alpha hydroxy acids and derivatives | I/Q | Plays a role in several biochemical processes and is produced in the muscles during intense activity |
| Myoinositol | Alcohols and polyols | I/Q | Involved in the Inositol phosphate metabolism and the Phosphatidylinositol signaling system. |
| Glucose-1-phosphate | Carbohydrates and carbohydrate conjugates | I/Q | Glycogenolysis produces glucose-1-phosphate and no energy. |
| Maltose | Carbohydrates and carbohydrate conjugates | I/Q | Maltose can be broken down into two glucose molecules |
| Glucose | Carbohydrates and carbohydrate conjugates | I | Primary source of energy |
| Succinate | Dicarboxylic acids and derivatives | I/Q | Component of the citric acid or TCA cycle and is capable of donating electrons to the electron transfer chain. |
| Formate | Carboxylic acids | I | Essential intermediary metabolite in folate-mediated one-carbon metabolism |
| Acetate | Carboxylic acid derivates | I/Q | Acetate in the form of acetyl CoA is used in metabolism to yield chemical energy. |
| Acetone | Carbonyl compounds | I/Q | One of the ketone bodies produced during ketoacidosis. Since ketosis develops under serious metabolic circumstances, all the mechanisms that balance or moderate the effects of ketosis enhance the chance for survival. |
1 Information detailed on the table was obtained from “The human metabolome database” (http://www.hmdb.ca/).
Concentrations of metabolites in bovine oviductal extracellular vesicles according to the stage of the estrous cycle and the side relative to ovulation (ipsilateral vs. contralateral). Data are given as means ± SEM of nmoL mg−1 of oEV proteins.
| Pre-Ovulatory | Post-Ovulatory | Mid-Luteal | Late-Luteal | |||||
|---|---|---|---|---|---|---|---|---|
| Ipsi | Contra | Ipsi | Contra | Ipsi | Contra | Ipsi | Contra | |
| Acetate | 2.5 ± 0.6 | 2.8 ± 0.1 | 2.7 ± 0.2 | 2.7 ± 0.2 | 2.9 ± 0.3 | 2.8 ± 0.0 | 2.8 ± 0.2 | 2.8 ± 0.2 |
| Acetone | 0.6 ± 0.2 | 0.7 ± 0.0 | 0.9 ± 0.0 | 0.9 ± 0.0 | 1.0 ± 0.1 | 0.9 ± 0.0 | 1.0 ± 0.1 | 0.9 ± 0.0 |
| Alanine | 16.7 ± 3.7 | 18.1 ± 0.9 | 15.5 ± 1.6 | 14.9 ± 1.4 | 15.5 ± 2.3 | 13.8 ± 0.3 | 13.4 ± 0.9 | 13.8 ± 1.6 |
| Carnitine | 4.8 ± 0.8 | 6.1 ± 0.2 | 4.3 ± 0.4 | 4.9 ± 0.6 | 5.5 ± 0.6 | 5.7 ± 0.9 | 5.5 ± 0.8 | 5.6 ± 0.8 |
| Choline | 8.8 ± 1.6 | 9.4 ± 0.5 | 10.9 ± 0.9 | 9.7 ± 0.8 | 10.3 ± 1.7 | 10.2 ± 0.4 | 8.6 ± 0.4 | 9.5 ± 1.2 |
| Creatine | 7.8 ± 1.8 | 8.4 ± 0.4 | 7.7 ± 0.6 | 7.8 ± 0.6 | 7.9 ± 0.9 | 7.9 ± 0.5 | 7.7 ± 0.6 | 7.7 ± 0.9 |
| Glucose-1-phosphate | 1.1 ± 0.6 | 0.7 ± 0.5 | 0.8 ± 0.5 | 3.1 ± 1.5 | 9.8 ± 2.1 | 39.5 ± 5.7 | 87.2 ± 41.8 | 117.1 ± 1.4 |
| Glycine | 25.2 ± 5.0 | 31.4 ± 5.7 | 30.8 ± 3.1 | 25.0 ± 2.1 | 39.3 ± 6.4 | 26.5 ± 0.9 | 27.5 ± 1.8 | 25.8 ± 4.2 |
| Isoleucine | 2.6 ± 0.5 | 3.2 ± 0.2 | 2.8 ± 0.3 | 2.6 ± 0.3 | 2.7 ± 0.3 | 2.5 ± 0.0 | 2.5 ± 0.4 | 2.4 ± 0.4 |
| Lactate | 33.0 ± 6.4 | 37.7 ± 2.4 | 36.7 ± 3.1 | 36.9 ± 2.5 | 43.0 ± 4.1 | 41.9 ± 2.7 | 43.3 ± 6.9 | 43.7 ± 6.1 |
| Maltose | 13.9 ± 5.0 | 19.1 ± 5.0 | 14.1 ± 1.7 | 29.3 ± 10.6 | 53.2 ± 4.3 | 110.5 ± 13.1 | 203.7 ± 9.7 | 225.1 ± 32.9 |
| Methionine | 10.0 ± 1.9 | 9.8 ± 0.6 | 8.7 ± 1.0 | 9.2 ± 1.0 | 7.3 ± 0.9 | 7.4 ± 0.6 | 6.2 ± 0.8 | 6.4 ± 0.8 |
| Myoinositol | 37.6 ± 7.9 | 41.5 ± 2.2 | 43.8 ± 4.2 | 44.4 ± 4.2 | 50.9 ± 5.5 | 51.5 ± 3.1 | 47.8 ± 5.7 | 50.4 ± 6.2 |
| Succinate | 0.7 ± 0.2 | 0.7 ± 0.0 | 0.9 ± 0.1 | 0.8 ± 0.1 | 1.1 ± 0.1 | 0.9 ± 0.1 | 1.0 ± 0.2 | 0.8 ± 0.2 |
| Valine | 3.2 ± 0.8 | 3.8 ± 0.2 | 3.3 ± 0.4 | 3.3 ± 0.4 | 3.2 ± 0.5 | 2.9 ± 0.0 | 2.7 ± 0.2 | 2.7 ± 0.2 |
Figure 2Comparative analysis of the oviduct EV metabolite content across the bovine estrous cycle. Principal component analysis (PCA) of metabolites measured in oEV at four different stages of the estrous cycle. S1, post-ovulation (red); S2, mid-luteal phase (blue); S3, late luteal phase (green) and S4, pre-ovulation (purple) from oviducts ipsilateral (triangles) and contralateral (round spots) to ovulation.
Figure 3Differential concentrations of specific bovine oEV metabolites across the estrus cycle. Maltose intra-oEV concentrations (nmol.mg−1 of EV protein, (a) was affected by the cycle stage and side of ovulation. Glucose-1-P (b), methionine (c) and acetone (d) intra-oEV concentrations were only influenced by the stage of the estrus cycle. For (b–d), ipsilateral and contralateral concentrations data were pooled as the side of ovulation did not show any significant effect on the metabolite level. (Post-ov: post-ovulatory phase; Mid-lut: mid-luteal phase; Late-lut: late lutal phase; Pre-ov: pre-ovulatory phase).
Over representation analysis of all identified metabolites in oEVs against pathway associated metabolite sets. The associated bar chart visualization of this analysis is shown in Figure 4.
| Pathway Associated Metabolite Sets 1 | Implicated Metabolites 2 | Total 3 | Hits 4 | Raw p 5 | Holm p 6 | FDR 7 |
|---|---|---|---|---|---|---|
| Glycine and serine metabolism | Creatine, Glycine, L-glutamic acid, L-alanine, L-threonine, L-methionine | 59 | 6 | 7.82 × 10−4 | 0.0766 | 0.0766 |
| Arginine and Proline Metabolism | Creatine, Glycine, L-glutamic acid, L-proline, Succinic acid | 53 | 5 | 0.00332 | 0.322 | 0.137 |
| Alanine metabolism | Glycine, L-glutamic acid, L-alanine | 17 | 3 | 0.00421 | 0.404 | 0.137 |
| Valine, Leucine and Isoleucine degradation | L-glutamic acid, L-isoleucine, Succinic acid, L-leucine, L-valine | 60 | 5 | 0.00575 | 0.546 | 0.141 |
| Glutathione Metabolism | Glycine, L-glutamic acid, L-alanine | 21 | 3 | 0.0078 | 0.734 | 0.146 |
| Carnitine Synthesis | L-carnitine, Glycine, Succinic acid | 22 | 3 | 0.00892 | 0.829 | 0.146 |
| Glutamate Metabolism | Glycine, L-glutamic acid, L-alanine, Succinic acid | 49 | 4 | 0.0152 | 1 | 0.212 |
| Phosphatidylethanolamine biosynthesis | Choline, Ethanolamine | 12 | 2 | 0.0234 | 1 | 0.267 |
| Ketone Body Metabolism | Succinic acid, Acetone | 13 | 2 | 0.0273 | 1 | 0.267 |
| Glucose-Alanine Cycle | L-glutamic acid, L-alanine | 13 | 2 | 0.0273 | 1 | 0.267 |
| Phosphatidylcholine biosynthesis | Choline, Ethanolamine | 14 | 2 | 0.0314 | 1 | 0.28 |
1 Only pathway associated metabolite sets with p < 0.05 are shown in the table; 2 Implicated metabolites from oEVs in the associated metabolite set; 3 Total number of metabolites in the metabolite set; 4 Hits: number of metabolites from oEVs involved in the metabolite set; 5 Raw p: original p value calculated from the enrichment analysis; 6 Holm p: adjusted raw p value by the Holm–Bonferroni method; 7 FDR: false discovery rate.
Figure 4Graphical overview of the over representation analysis (ORA) for all metabolites identified in bovine oEVs generated by MetaboAnalyst 4.0 web-based software. Pathway associated metabolite sets are sorted based on fold enrichment and p value. Further details on p-values and metabolites included in each pathway are detailed in Table 4.
Figure 5Graphical overview of the quantitative enrichment analysis for all metabolites quantified in bovine oEVs generated by MetaboAnalyst 4.0 web-based software. Pathway associated metabolite sets are sorted based on fold enrichment and p-value after comparison between stages. This bar chart was obtained by comparing Pre-ov vs. Late-lut stages. For each stage, ipsilateral and contralateral data were pooled. Further details on p-values and metabolites included in each pathway are detailed in Table 5.
Quantitative enrichment analysis of bovine oEV metabolites against pathway associated metabolite sets. Associated bar chart visualization of this analysis is shown in Figure 5.
| Pathway Associated Metabolite Sets 1 | Implicated Metabolites 2 | Total 3 | Hits 4 | Raw p 5 | Holm p 6 | FDR 7 |
|---|---|---|---|---|---|---|
| Starch and sucrose metabolism | D-maltose, Glucose-1-phosphate | 31 | 2 | 3.21 × 10−5 | 0.0015 | 6.835 × 10−4 |
| Nucleotide sugars metabolism | Glucose-1-phosphate | 20 | 1 | 8.651 × 10−5 | 0.0039 | 6.835 × 10−4 |
| Glycolysis | Glucose-1-phosphate | 25 | 1 | 8.651 × 10−5 | 0.0039 | 6.835 × 10−4 |
| Lactose synthesis | Glucose-1-phosphate | 20 | 1 | 8.651 × 10−5 | 0.0039 | 6.835 × 10−4 |
| Gluconeogenesis | Glucose-1-phosphate, L-lactic acid | 35 | 2 | 8.662 × 10−5 | 0.0039 | 6.835 × 10−4 |
| Galactose metabolism | Myoinositol, Glucose-1-phosphate | 38 | 2 | 8.726 × 10−5 | 0.1933 | 6.835 × 10−4 |
| Spermidine and spermine biosynthesis | L-methionine | 18 | 1 | 0.0047 | 0.4906 | 0.032 |
| Betaine metabolism | Choline, L-methionine | 21 | 2 | 0.0123 | 1 | 0.072 |
| Methionine metabolism | Choline, Glycine, L-methionine | 43 | 3 | 0.0438 | 1 | 1 |
1 Only pathway associated metabolite sets with p < 0.05 are shown in the table; 2 Implicated metabolites from oEV in the associated metabolite set; 3 Total number of metabolites in the metabolite set; 4 Hits: number of metabolites from oEV involved in the metabolite set; 5 Raw p: original p value calculated from the enrichment analysis; 6 Holm p: adjusted raw p value by the Holm–Bonferroni method; 7 FDR: false discovery rate.